Breaking News
FONT-SIZE Plus   Neg
Share SHARE

FDA Refuses To Approve Alexza's Adasuve On Manufacturing Issues, Shares Plunge

RELATED NEWS
Trade ALXA now with 

Alexza Pharmaceuticals, Inc. (ALXA: Quote) Thursday said it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its New Drug Application for Adasuve (loxapine) inhalation powder, 5 mg and 10 mg, citing manufacturing deficiencies at its Mountain View, California facility. The stock fell about 37 percent in the extended trade.

Adasuve is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The letter indicated that the NDA review cycle was complete and the application was not ready for approval in its present form.

The FDA said in the letter, "During a recent inspection of the Mountain View, CA manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved."

The company had received a CRL from the FDA previously in October 2010, citing breathing-related concerns associated with Adasuve.

Alexza said Thursday that it believes the deficiencies in the latest CRL concern medical devices and can be addressed readily. The company said there were no new clinical or safety issues identified and there were no other deficiencies outlined in the CRL issued by FDA's Center for Drug Evaluation and Research.

Regarding the Adasuve Risk Evaluation and Mitigation Strategy or REMS, the CRL said discussions could continue on the proposed REMS after submitting the response to the action letter.

The CRL also contained comments on Alexza's draft product labeling. The company believes that it has substantial agreement with the FDA on the REMS and product labeling.

Alexza plans to meet with the FDA as soon as practical to gain a better understanding of the specific deficiencies.

The firm said it looks forward to working to resolve the remaining issues in a timely manner.

ALXA closed on Thursday at $0.61, down $0.08 or 11.59 percent from the previous close, on 11.54 million shares compared to the 3-month average volume of 1.48 million shares. The stock declined $0.32 or 36.9 percent in the extended trade.

Register
To receive FREE breaking news email alerts for Alexza Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The U.K. economy grew at a slower pace in the third quarter in the face of rising uncertainty stemming from global economic conditions, preliminary estimates from the Office for National Statistics Office showed Friday. Gross domestic product climbed 0.7 percent from the second quarter, when it grew 0.9 percent. German consumer climate is set to improve slightly in November, ending the downward trend, as income expectations among households strengthened on the back of the strong labor market situation, survey data revealed Friday.The forward-looking consumer confidence index rose slightly to 8.5 in November from 8.4 in October. Software giant Microsoft Corp. said Thursday after the markets closed that its first quarter profit fell 13% from last year, hurt mainly by integration and restructuring costs even as revenue surged 25% thanks to strong sales of its gadgets and cloud-based products. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.